GCG and digestive system disorder: In addition, similar to other GLP-1 RAs, subcutaneous and oral semaglutide administration may also induce mild-to-moderate gastrointestinal system disorders, which remains a safety concern and serves as the primary reason for discontinuation of treatment, albeit with a standard dose-escalation procedure (Smits and Van Raalte, 2021).